Ropeginterferon alfa-2b for the treatment of patients with polycythemia vera.

@article{Wagner2020RopeginterferonAF,
  title={Ropeginterferon alfa-2b for the treatment of patients with polycythemia vera.},
  author={Sandro M. Wagner and Thomas Melchardt and Richard Greil},
  journal={Drugs of today},
  year={2020},
  volume={56 3},
  pages={
          195-202
        }
}
Ropeginterferon alfa-2b is a novel mono-PEGylated alfa interferon. It is the first interferon approved for the treatment of patients with polycythemia vera (PV) and the first and only approved treatment for PV independent of previous hydroxyurea exposure. In contrast to other interferons, the drug has to be subcutaneously injected every 2 weeks only, with intervals of 4 weeks being possible after prolonged use. It is generally well tolerated and can lead to deep molecular responses. In this… 

A pharmacokinetic evaluation of ropeginterferon alfa-2b in the treatment of polycythemia vera

Clinical data suggests that the compound may provide a disease-modifying option for PV patients with asymptomatic splenomegaly, representing a significant improvement compared to conventional cytoreductive therapies.

Pharmacokinetics and Pharmacodynamics of Novel Long-Acting Ropeginterferon Alfa-2b in Healthy Chinese Subjects

Ropeginterferon alfa-2b is safe and well tolerated after a single subcutaneous injection up to 270 mcg in healthy Chinese and the pharmacokinetics, pharmacodynamics and safety profiles and safety of the product are evaluated.

Pharmacokinetics and Pharmacodynamics of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects After Single Subcutaneous Administration

Ropeginterferon alfa-2b up to 300 µg was safe and well tolerated, with no unexpected safety findings based on previous experiences with ropeginterferonAlfa- 2b and other forms of interferon.

The Role of Neutrophilic Granulocytes in Philadelphia Chromosome Negative Myeloproliferative Neoplasms

The molecular biology underlying myeloproliferative neoplasms is discussed and the central role of leukocytosis and, specifically, neutrophilic granulocytes is pointed out in this group of disorders.

Circulating Type I Interferon Levels and COVID-19 Severity: A Systematic Review and Meta-Analysis

Peripheral IFN-α cannot be used as a severity marker as it does not determine the clinical status presented by COVID-19 patients.

Real-world clinical outcomes of patients with myelofibrosis treated with ruxolitinib: a medical record review.

There is an unmet need for more effective treatments for patients with myelofibrosis who failed ruxolitinib, according to the results of this large, real-world study.

Trends and Perspectives of Biological Drug Approvals by the FDA: A Review from 2015 to 2021

The number of drugs included in this class grew over this period, totaling 90 approvals, with an average of 13 authorizations per year, which contrasts with previous periods, which registered between 2 and 8 approvals per year.